On March 7, 2014, Oasmia completed a private placement which, according to plan, provided the company with MSEK 68 after issue expenses.

“We now have the freedom of action to continue working with our prioritized projects”, says Oasmia CEO Julian Aleksov.

Notes to editors:

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).